Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria

The development of therapeutics depends on predictions of clinical activity from pre-clinical data. We have previously described SYNB1618, an engineered bacterial therapeutic (synthetic biotic) for the treatment of Phenylketonuria (PKU), a rare genetic disease that leads to accumulation of plasma ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Charbonneau, Mark R., Denney, William S., Horvath, Nicholas G., Cantarella, Pasquale, Castillo, Mary J., Puurunen, Marja K., Brennan, Aoife M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298439/
https://www.ncbi.nlm.nih.gov/pubmed/34294862
http://dx.doi.org/10.1038/s42003-021-02183-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298439/
https://www.ncbi.nlm.nih.gov/pubmed/34294862
http://dx.doi.org/10.1038/s42003-021-02183-1

Ejemplares similares